Clinical Trial 21742

• Overview

  Study Title:

  Remote Resistance Exercise Powering Survivors- Gastrointestinal Oncology (Remote REPS-:GI)

  Summary:

  The purpose of the study is to evaluate a tele-resistance training exercise program for individuals undergoing chemotherapy for advanced upper gastrointestinal cancer.

  Objective:

  Specific Aim #1 Evaluate the feasibility (enrollment, retention, and adherence to exercise sessions and prescribed exercise volumes), safety, and acceptability of a 12-week tele-RT intervention during first-line chemotherapy for advanced upper GI cancer. Specific Aim #2 Compare 12-week changes in muscular strength and muscular endurance, skeletal muscle index (SMI) and skeletal muscle density (SMD), quality of life, fatigue, and physical functioning between patients randomized to tele-RT vs. usual care (UC) during first-line chemotherapy for advanced upper GI cancer.

• Inclusion Criteria

  • Age >18 years
  • Biopsy-proven upper GI cancer, stage III-IV
  • ECOG performance status 0-1
  • Treatment plan of chemotherapy with planned return to Moffitt Cancer Center for restaging
  • Able to read and speak English fluently
  • Capable of providing informed consent

• Exclusion Criteria

  • Regular engagement in RT (2x/week targeting all major muscle groups)
  • Screen failure for exercise safety based on Physical Activity Readiness Questionnaire (PAR-Q) and Patient-Reported Measurement Information System (PROMIS) screening questions
  • Underlying unstable cardiac or pulmonary disease or symptomatic cardiac disease (New York Heart Association functional class III or IV).
  • Recent fracture or acute musculoskeletal injury that precludes ability to participate in RT
  • Numeric pain rating scale of >7 out of 10
  • Myopathic or rheumatologic disease that impacts physical function

If you are interested in learning more about clinical trials, our clinical trial navigators can discuss your options and recommend opportunities that may be suitable for you. Call 813-745-6100 or 1-800-679-0775 (toll-free) or submit a clinical trials inquiry form.